Estimations des analystes de Wall Street pour Innate Pharma S.A. (IPHA): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Consensus des analystes
| Achat fort | 0 |
| Achat | 4 |
| Conserver | 2 |
| Vente | 0 |
| Vente forte | 0 |
| Analystes au total | 6 |
| Note moyenne (1-5) | 0.67 |
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-09-17 | $-0.29 | ||
| 2026-05-13 | $-0.35 | $-0.35 | +0.8% |
| 2025-11-13 | $-0.30 | $-0.33 | +9.8% |
| 2025-05-13 | $-0.35 | $-0.27 | -29.5% |
| 2024-11-13 | $-0.34 | $-0.30 | -14.0% |
| 2024-05-14 | $-0.13 | $-0.44 | +70.1% |
| 2023-09-14 | $0.02 | $0.09 | -75.2% |
| 2023-03-23 | $-0.88 | $-0.41 | -117.2% |
Ratios de valorisation
| Prix / Valeur comptable | -6.93 |
| EV / EBITDA | -2.50 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $56.2M | $32.6M | $79.9M | $69.0M | $69.8M | $12.1M | $57.7M | $51.9M | $12.6M | $2.8M |
| Coût des Ventes | $48.6M | $67.0M | $69.6M | $45.2M | $49.7M | $47.0M | $51.7M | $56.0M | $52.0M | 0 |
| Marge Brute | $7.5M | -$34.4M | $10.3M | $23.8M | $20.1M | -$22.3M | $6.0M | $5.6M | $12.6M | $2.8M |
| R&D | $48.6M | $67.0M | $69.6M | $1.6M | $49.7M | $47.0M | $51.7M | $56.0M | $52.0M | $43.6M |
| Frais Généraux | $9.3M | $16.2M | $19.3M | $49.6M | $19.0M | $25.5M | $14.5M | $11.7M | $11.9M | $11.0M |
| Charges Opérationnelles | $48.6M | $72.6M | $74.7M | $50.9M | $19.0M | $25.5M | $63.4M | $18.3M | $64.2M | $56.2M |
| Résultat Opérationnel | $7.6M | -$40.0M | $5.1M | -$27.1M | $1.1M | -$47.8M | -$57.4M | -$12.7M | -$51.6M | -$53.4M |
| EBITDA | $10.8M | -$35.6M | -$3.3M | -$20.9M | $13.3M | -$43.2M | -$12.3M | -$1.8M | -$46.9M | -$43.6M |
| Charges d'Intérêt | $124000 | $113000 | $102000 | $229445 | $341000 | $312000 | $288000 | $640000 | $566000 | $440000 |
| Résultat Avant Impôts | $12.9M | -$48.0M | $2.7M | -$20.8M | -$829000 | -$45.5M | -$58.0M | -$7.6M | -$49.5M | -$49.2M |
| Impôts | $301000 | $368000 | -$333000 | $206000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Résultat Net | $12.6M | -$48.4M | $3.0M | -$20.8M | -$64.0M | -$52.8M | -$58.1M | -$7.6M | -$49.5M | -$49.2M |
| BPA | $0.23 | $-0.89 | $0.05 | $-0.31 | $-0.01 | $-0.57 | $-0.73 | $-0.09 | $-0.61 | $-0.53 |
| BPA Dilué | $0.23 | $-0.89 | $0.05 | $-0.31 | $-0.01 | $-0.57 | $-0.73 | $-0.09 | $-0.61 | $-0.53 |
| Actions en Circulation (Diluées) | $53.9M | $54.4M | $58.8M | $66.9M | $78.9M | $79.5M | $79.6M | $84.1M | $81.1M | $89.4M |
Prix
| Prix | $2.01 |
| Capitalisation | $189M |
| Bourse | NASDAQ |
| Pays | FR |
Entreprises liées: APLT · CGEN · CRBP · CRDF · CYBN · ELTX · MIST
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de IPHA: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions